Posted by ABMN Staff on Apr 24th, 2024
Oppenheimer upgraded shares of AtriCure (NASDAQ:ATRC – Free Report) from a market perform rating to an outperform rating in a report released on Tuesday morning, MarketBeat reports. They currently have $32.00 price objective...
More of this article »